⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13411447 | 0.84 | ALDH1A1 (0.32) | — | |
| SCHEMBL6176534 | 0.81 | MAPK1 (0.40) | — | |
| SCHEMBL212537 | 0.74 | MAPK1 (0.36) | — | |
| SCHEMBL17082466 | 0.74 | MAPK1 (0.36) | — | |
| SCHEMBL9969579 | 0.74 | ALDH1A1 (0.31) | — | |
| SCHEMBL18840290 | 0.74 | — | — | |
| SCHEMBL13120930 | 0.73 | — | — | |
| SCHEMBL12219286 | 0.73 | — | — | |
| SCHEMBL16523870 | 0.73 | — | — | |
| SCHEMBL9957600 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4140991-B1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | PROMEGA CORP (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-3562823-B1 | FUNCTIONALIZED NANOLUC INHIBITORS | PROMEGA CORP (US) | 2023-02-08 | — | — | EP | disclosed |
| US-11390599-B2 | Inhibitors of oplophorus luciferase-derived bioluminescent complexes | PROMEGA CORPORATION (US) | 2022-07-19 | — | — | US | disclosed |
| CN-107922428-B | Thienopyrrole compounds and their use as inhibitors of oplophorus-derived luciferase | 普洛麦格公司 | 2021-02-05 | — | — | CN | disclosed |
| US-10815247-B2 | Functionalized NANOLUC inhibitors | PROMEGA CORPORATION (US) | 2020-10-27 | — | — | US | disclosed |
| EP-3313846-B1 | THIENOPYRROLE COMPOUNDS AND USES THEREOF AS INHIBITORS OF OPLOPHORUS-DERIVED LUCIFERASES | PROMEGA CORP (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20200063110-A1 | THIENOPYRROLE COMPOUNDS AND USES THEREOF | PROMEGA CORPORATION | 2020-02-27 | — | — | US | disclosed |
| EP-3562823-A1 | FUNCTIONALIZED NANOLUC INHIBITORS | Promega Corporation (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20180222916-A1 | FUNCTIONALIZED NANOLUC INHIBITORS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| WO-2018125992-A1 | FUNCTIONALIZED NANOLUC INHIBITORS | PROMEGA CORPORATION (US) | 2018-07-05 | — | — | WO | disclosed |
| US-6191140-B1 | POTASSIUM CHANNEL MODULATORS; MUSCLE RELAXANTS; CONTROLLING CELL MEMBRANES | ABBOTT LABORATORIES | 2001-02-20 | — | — | US | disclosed |
| WO-2000078768-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | disclosed |
| EP-0763524-B1 | Urea and amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prophylactic use | SANKYO CO (JP) | 2000-08-23 | — | — | EP | disclosed |
| WO-2000024743-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| WO-2000024741-A2 | DIHYDROPYRIDINE COMPOUNDS AND THEIR USE AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| WO-2000024719-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| US-6040339-A | TREATMENT AND PROPHYLAXIS OF HYPERCHOLESTEREMIA OR ARTERIOSCLEROSIS IN A MAMMAL | SANKYO COMPANY, LIMITED (JP) | 2000-03-21 | — | — | US | disclosed |
| EP-0945445-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
| US-5880147-A | Amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prohylactic use | SANKYO COMPANY, LIMITED (JP) | 1999-03-09 | — | — | US | disclosed |
| EP-0763524-A1 | Urea and amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prophylactic use | SANKYO COMPANY LIMITED (JP) | 1997-03-19 | — | — | EP | disclosed |